Stifel cuts Arrowhead Pharma stock price target on Tryngolza launch
Stifel reduced its price target for Arrowhead Pharmaceuticals (ARWR) to $96 from $104, citing weaker-than-expected Tryngolza launch results. The stock has fallen 19% in a week, trading at $47.15. Despite this, Arrowhead and partner Ionis maintain confidence in peak sales targets. The company reported a wider loss for fiscal 2026, but revenue of $450.8 million exceeded expectations, driven by REDEMPLO launch momentum.
How this was made
The 30-second read
Why it matters
The price‑target reduction signals near‑term downside, but the company retains long‑term upside on its pipeline.
Market read
Analyst downgrade creates short‑term sell pressure; investors should reassess exposure to ARWR.
What to watch
Potential upside if later data from Tryngolza or sHTG exceeds expectations.
Background
Arrowhead Pharmaceuticals recently launched Tryngolza, an sHTG therapy, and reported a wider fiscal 2026 loss despite revenue beat.
Ticker impact
Stifel lowered Arrowhead Pharmaceuticals (ARWR) price target to $96 from $104 after weaker-than-expected Tryngolza launch.
likely pressure as the market prices in weaker launch data and lower target.
Target cut is a fresh analyst action tied to a specific product launch, providing a clear catalyst for short‑term sell pressure.
Market effects
May weigh on other biotech firms with similar sHTG pipelines.
Limited to U.S. biotech sector.
Low global impact beyond niche biotech investors.
Counterpoint
Long‑term investors may view the target cut as an overreaction given long‑term pipeline optimism.
Key entities
- companyArrowhead Pharmaceuticals
Biotech firm developing sHTG therapies.
- analystStifel
Equity research firm that lowered the price target.
